PDCD1 and central nervous system cancer: Survival of glioma mice was significantly prolonged by combination therapy (median survival, 67 days) compared with treatment with NaB or an anti-mouse PD-1 mAb alone (median survival, 54.5 and 56.5 days, respectively).